London, UK (PRWEB) September 11, 2012
Stroke Prevention in Atrial Fibrillation (SPAF) represents the largest opportunity for the new generation oral anticoagulants, besides a very large prevalence, there is a very clear unmet need. There are 1.7 million patients in the US treated for non-valvular atrial Fibrillation with warfarin, in Europe the prevalence is almost twice and in Japan there are close to 1 million patients.
About 35% of the AF patients are currently not treated with warfarin because of warfarin related constraints (drug-drug /dietary interactions, difficulty in INR control). Hypothetically assuming a 100% market share shift from warfarin/aspirin/other therapies to new generation oral anticoagulants, the annual market size works out to be USD 22 billion (at USD 3000 as annual cost of therapy). Besides the new generation oral anticoagulants, there is also the watchman device (currently in Phase 3) from Boston Scientific, which as well could be a major contender of market share.
New research study “Edoxaban - Potential Game Changer in Oral Anticoagulant Market” developed by MP Advisors has been recently published by Market Publishers Ltd.
Title: Edoxaban - Potential Game Changer in Oral Anticoagulant Market
Published: September, 2012
Price: US$ 1,000.00
The research study investigates the potential of Edoxaban in the world of new generation oral anticoagulants.
The report also has a market model for the novel oral anticoagulants, which is categorized into three segments: warfarin treated patients; aspirin treated patients; patients on dual anti-platelet therapy / patients on no therapy. A market model for each of these market segments is separately prepared for the major geographies – Japan, the EU and the US.
Companies discussed include: Daiichi Sankyo, Bayer, Johnson and Johnson, Boston Scientific, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, and Portola.
Market Model for Stroke Prevention in Atrial Fibrillation and DVT Treatment
Why is Edoxaban a potential Mega Blockbuster
Edoxaban – Market potential
Compared to other oral next generation anticoagulants
Our view on key upcoming Milestones For Edoxaban and Factor Xa class
Estimated launch timelines for new generation anticoagulants–Indication wise/Geographywise
2. Edoxaban in SPAF
Background information on Edoxaban (Lixiana)
Edoxaban PK/PD data comparision to other novel oral anticoagulant
Expectations from ENGAGE AF study
ENGAGE AF Clinical trial design comparison to other Clinical trial designs
Analysis of chronology of events happened in completion of ENGAGE AF
Analysis of the reported clinical trial results of Edoxaban
PhII data in Japanese Patient pool
PhII data in Global Patient Pool
PhII data in Taiwan patient pool
Japan- PhII/III clinical data comparision of Edoxaban with other oral anticoagulants
Relative clinical profile and Positioning of Edoxaban compared to Xarelto, Eliquis and Pradaxa in different geographies
3. Edoxaban Market Positioning in SPAF, Market Model and Peak Sales
Estimates Based on:
Switch From Warfarin
Warfarin continues to hold itself strong against Pradaxa and Xarelto – Will the entry of Eliquis / Edoxaban change the scenario?
Switch from Aspirin
Switch/Addition to those on dual antiplatelets
Geographywise clinical data difference and different clinical practise results in different market leader/market share
Risk to our market share Forecast
4. Factors that will Restrict Adoption of New Generation Oral
Anticoagulants post launch
Experts view on the hurdles to the adoption of new generation anticoagulants in SPAF at ESC-12
Concomitant Medicines - Donut hole and drug-drug interaction
Availability of antidote for novel oral anticoagulants
Regulatory Scenario – Medicare Shared Saving program to be implemented in 2012
Reimbursement status of PT/INR monitoring for warfarin in major countries
Warfarin Genotype testing, its Regulatory Approval And Its Reimbursement
5. Edoxaban In VTE Treatment
Edoxaban Clinical Profile compared to Other Factor Xa inhibitor in VTE treatment
Results from PhII BOTTICELI study of Eliquis
Expected data from HOKUSAI VTE study
Pros and Cons of Edoxaban market potential in VTE treatment
Annexure - 1: Analysis of the Reported Pivotal Clinical Study Results of Next Generation Oral Anticoagulants (Pradaxa, Eliquis, and Xarelto) in SPAF
More new market research studies by the publisher can be found at MP Advisors page.